67356 Federal Register / Vol. 71, No. 224 / Tuesday, November 21, 2006 / Notices 

Implementation. ANA is proposing 

three distinct priority areas within the 

Native Language program area. The 

proposed categories are: 

Category I: Language Assessment will 

remain as a 12-month project period 

with the primary activity of assessing 

the current status of the Native 

Language for the identified Native 

community. 

Category II: Language Project Planning 

will have up to 24-month project period 

with the primary activity of planning a 

Native Language project for the Native 

community to be impacted by the 

project. 

Category III: Language Project 

Implementation will have up to a 36- 

month project period to support such 

activities consistent with legislative and 

regulatory requirements. 

An award in Categories II and III is 

not contingent upon having received 

previous funding from ANA for 

language preservation and maintenance; 

however, current language-assessment 

data and language-delivery methods 

will need to be provided. (Legal 

authority: Section 803(a) and (d) and 

803C of the Native Americans Programs 

Act of 1974, as amended, 42 U.S.C. 

2991b and 2991b–c. 

III. Application—Project Development 

During the FY 2006 competitions, 

ANA participated in the electronic 

application submission process. Based 

upon this experience, ANA has 

analyzed the submission procedure. To 

eliminate future concerns with 

uploading attachments, ANA has 

determined that all applications (hardcopy and electronic) should be 

submitted with no more than three (3) 

objectives per 12-month budget period 

for any given competition. This 

limitation will still allow an applicant 

to convey adequately the proposed 

project goals, activities and results 

expected. (Legal authority: Section 803 

(a) and (d) and 803C of the Native 

American Programs Act of 1974, as 

amended, 42 U.S.C. 2991b and 2991b–

3.) 

IV. Special Initiative 

Under legislative authority, ANA can 

provide funding for Special Initiatives 

that focus on specifically identified 

needs within Native communities. 

Applicants must submit projects that are 

responsive to the specific competitive 

program area. Last year ANA offered a 

specific program announcement to fund 

projects that support healthy families 

titled, Improving the Well-Being of 

Children—Native American Healthy 

Marriage Initiative (NAHMI). This 

Special Initiative will be supported 

again in FY 2007. Applicants requesting 

funding for these types of initiatives 

will need to submit projects under this 

designated Special Initiative 

competitive area only. (Legal authority: 

Section 803 (a) and (d) and 803C of the 

Native American Programs Act of 1974, 

as amended, 42 U.S.C. 2991b and 

2991b–3. 

V. ANA Funding Restriction Policy 

In order to ensure that ANA manages 

proper fiscal responsibility in the 

dispensing of Federal funds, a list of 

actions and activities, which will not be 

considered as eligible activities for 

funding, is maintained. ANA has 

observed that projects including such 

contingency activities as permits, 

licenses, outside or internal 

certification, Federal or State agency 

approvals, or project activities that are 

contingent on the outcome of a court 

decision, do not complete projects 

within the approved project period. As 

a result of these situation, grantees often 

do not complete project objectives or 

expend approved funding. Based upon 

agency reviews and on-site visits, ANA 

will implement the following new 

funding restriction policy: 

ANA will not consider projects that 

contain contingency activities that impede or 

indefinitely delay the ongoing progress of the 

proposed project. Applicants must 

demonstrate the project planning considered 

potential contingency activities and provide 

adequate assurance that such activities will 

not impede the progress of the project. (Legal 

authority: Section 803 (a) and (d) and 803C 

of the Native American Programs Act of 

1974, as amended, 42 U.S.C. 2991b and 

2991b–3. 

Dated: November 9, 2006. 

Sheila K. Cooper, 

Director of Program Operations, 

Administration for Native Americans. 

[FR Doc. 06–9281 Filed 11–21–06; 8:45 am] 

BILLING CODE 4184–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. 2006N–0464] 

Electronic Submission of Regulatory 

Information, and Creating an 

Electronic Platform for Enhanced 

Information Management; Public 

Hearing 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice of public hearing; request 

for comment. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing a 

public hearing to solicit general views 

and information from interested persons 

on issues concerning the electronic 

submission of product information to 

the agency. In particular, FDA is seeking 

these views and information from 

interested persons on the feasibility and 

effect of an all-electronic submission 

environment, as well as issues related to 

an electronic regulatory information 

exchange platform. To help solicit such 

information and views, FDA is seeking 

responses to specific questions (see 

section IV of this document). 

DATES: Public Hearing: The public 

hearing will be held on December 18, 

2006, from 9 a.m. to 5 p.m. However, 

depending on the level of public 

participation, the meeting may be 

extended or may end early. 

Registration and Participation: 

Registration on the day of the public 

hearing will be provided on a space 

available basis beginning at 7:30 a.m. 

Because seating is limited, we 

recommend arriving early. See section I 

of the SUPPLEMENTARY INFORMATION

section of this document for information 

on how to participate in the meeting. If 

you need special accommodations due 

to a disability, please contact Paula S. 

McKeever (see FOR FURTHER INFORMATION

CONTACT) at least 7 days in advance. 

Comments: Submit written or 

electronic notices of participation and 

comments by December 8, 2006. The 

administrative record of the hearing will 

remain open to receive additional 

comments until February 16, 2007. 

ADDRESSES: The public hearing will be 

held at the Advisors and Consultants 

Staff Conference Room, Food and Drug 

Administration, 5630 Fishers Lane, 

Rockville, MD 20857. Additional 

information on parking and public 

transportation may be accessed at http:// 

www.fda.gov/oc/initiatives/ 

criticalpath/. 

Submit written notices of 

participation and comments to the 

Division of Dockets Management (HFA–

305), Food and Drug Administration, 

5630 Fishers Lane, rm. 1061, Rockville, 

MD 20857. Submit electronic notices of 

participation and comments to http:// 

www.accessdata.fda.gov/scripts/oc/ 

dockets/comments/commentdocket.cfm. 

Identify all submissions to the docket 

with the docket number found in 

brackets in the heading of this 

document. 

FOR FURTHER INFORMATION CONTACT: 

Paula S. McKeever, Office of Critical 

Path Programs (HF–18), Food and Drug 

Administration, 5600 Fishers Lane, rm. 

14B–45, Rockville, MD 20857, 301–827–

1520, paula.mckeever@fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: 


sroberts on PROD1PC70 with NOTICES
Federal Register / Vol. 71, No. 224 / Tuesday, November 21, 2006 / Notices 67357 

I. How to Participate in the Meeting 

The procedures governing the hearing 

are set forth in part 15 (21 CFR part 15) 

of FDA’s regulations. If you wish to 

make an oral presentation during the 

hearing, you must submit a written 

notice of participation with the Division 

of Dockets Management (see ADDRESSES) 

by December 8, 2006. In the written 

notice, submit your name, title, business 

affiliation, address, telephone number, 

fax number, and e-mail address. You 

should also submit a written statement 

for each discussion topic in section IV 

of this document that you intend to 

address, or other pertinent information 

related to the topic in your presentation, 

the names and addresses of all 

individuals that plan to participate, and 

the approximate time requested for your 

presentation. We encourage individuals 

and organizations with common 

interests to consolidate or coordinate 

their presentations to allow adequate 

time for each request for presentation. 

Participants should submit to the docket 

two copies of each presentation. 

We will file the hearing schedule 

indicating the order of presentation and 

the time allotted to each person with the 

Division of Dockets Management (see 

ADDRESSES). We will also mail or 

telephone the schedule to each 

participant before the hearing. In 

anticipation of the hearing presentations 

moving ahead of schedule, participants 

are encouraged to arrive early to ensure 

their designated order of presentation. 

Participants who are not present when 

called, risk forfeiting their scheduled 

time. 

II. Background 

Over the past decade, we have been 

moving toward transforming all 

regulatory submissions from paper to 

electronic means. To meet this goal, we 

have taken the following steps: 

• Issued regulations related to 

voluntary electronic submission of 

regulatory information and provided a 

docket listing all submissions that we 

accept electronically (e.g., electronic 

records and electronic signatures, 21 

CFR part 11; docket 92S–0251; http:// 

www.fda.gov/ohrms/dockets/dockets/ 

92s0251/92s0251.htm); 

• Issued regulations requiring or 

proposing to require electronic 

submission of certain regulatory 

information (e.g., the electronic 

submission of the content of labeling 

(December 11, 2003; 68 FR 69009), and 

manufacturer registration and listing of 

drug products (August 29, 2006; 71 FR 

51275)); 

• Issued numerous guidance 

documents to assist in the submission of 

various regulatory documents in 

electronic format (e.g., electronic 

common technical document, certain 

premarket applications, and 

postmarketing information; see http:// 

www.fda.gov/cder/guidance/ 

index.htm#electronic%20submissions); 

• Issued notices related to electronic 

submission (e.g., availability of the FDA 

electronic submissions gateway (http:// 

www.fda.gov/esg/default.htm)); and 

• Collaborated with manufacturers, 

health care information suppliers, and 

other government agencies to develop 

data standards, and to build databases 

for sharing certain clinical trial 

information. 

Now that we have accomplished these 

preliminary steps, we are considering 

technological and other feasibility 

issues related to the electronic 

submission of premarket applications to 

FDA , as well as the electronic 

submission of other regulatory 

information (e.g., postmarketing 

information and amendments to 

applications). 

Facilitating electronic submissions 

and the electronic availability of 

product information would promote 

patient safety and better health 

outcomes, speed development of new 

medical technology, and allow health 

care professionals and consumers to 

make well informed decisions regarding 

the use of medical products. Such 

facilitations of electronic submissions 

would also support the Secretary’s 

health IT priorities to harness 

information technology to improve 

healthcare and patient safety. 

As we work towards establishing a 

modern, paperless submission 

environment, we have also become 

aware of the potential benefits of a 

common electronic platform that could 

be administered by a third party entity 

or entities (e.g. private or nonprofit 

entities not otherwise engaged in 

clinical research activities) with 

relevant expertise and organizational 

leadership to facilitate, coordinate and 

manage the functions necessary for 

electronic submissions. For example, a 

third party entity might perform the 

following tasks: 

• Build an electronic platform, 

• Maintain data warehouses, 

• Transition existing electronic data 

and information repositories to the 

electronic platform, 

• Produce other necessary 

components to facilitate electronic 

access and management of information, 

• Manage and support these 

functions. 

III. Purpose and Scope of the Hearing 

The purpose of this public hearing is 

to provide stakeholders the opportunity 

to address specific topics (see section IV 

of this document) and present their 

views, recommendations, and any other 

pertinent information related to the 

scope of this public hearing. 

The scope of this public hearing 

includes the following three issues: 

• Feasibility issues related to the 

electronic submission of premarket 

applications, including the effects on 

stakeholders of such actions; 

• Feasibility issues related to 

electronic submissions of other 

regulatory information, e.g., 

postmarketing information and 

amendments to applications; and 

• Issues related to the concept and 

feasibility of an electronic platform that 

would facilitate the exchange of clinical 

research information and other 

regulatory product information, the role 

of a public private partnership in the 

creation and assessment of such a 

platform, and the management of the 

platform after its creation by a private 

entity or entities with the relevant 

technological expertise. 

IV. Issues for Discussion 

A. Electronic Submissions 

We are specifically interested in 

hearing comments regarding the 

following questions and any other 

pertinent information related to the 

feasibility of the electronic submission 

of premarket applications and other 

regulatory information: 

1. Transition From Paper Submissions 

to Electronic Submissions 

• Since January 1999, we have 

accepted the voluntary electronic 

submission of certain premarket 

applications. If you are not voluntarily 

submitting such applications 

electronically, what is the reason(s)? 

• Are you electronically submitting 

any portion of your premarket 

application? Is the portion specific to 

product type or premarket application? 

• What are the major impediments to 

an all-electronic submission 

environment? 

• How can FDA best address these 

impediments? 

• Are there certain types of premarket 

applications or portions of applications 

that would be more difficult to submit 

electronically? Why? 

• Are there specific issues related to 

electronic submission of premarket 

applications that are unique to small 

companies, academic institutions, and 

government agencies? If so, what are 

they and why are they unique? 


sroberts on PROD1PC70 with NOTICES
67358 Federal Register / Vol. 71, No. 224 / Tuesday, November 21, 2006 / Notices 

• In addition to the sponsors of 

premarket applications, are there other 

sectors of FDA regulated industry that 

would have to make adjustments in 

business practices in an all-electronic 

submission environment? Please 

describe any such adjustments. 

• In your opinion, what internal 

expertise is needed for firms to make the 

transition to an all-electronic premarket 

submission? Do firms have this 

expertise? 

• Is the labor market ready to 

accommodate industry’s demand for 

such expertise to convert applications in 

an all-electronic submission 

environment? 

• Are there enough entities available 

to provide such services or tools in 

support of this effort? If not, how long 

would it take for these services to 

become available? 

• How would an all-electronic 

submission environment benefit you? 

• Would an all-electronic submission 

environment change your ability to 

initiate in a timely manner the studies 

supporting your regulatory submission? 

2. Cost 

• What do you estimate as the cost 

burden to you if all premarket 

applications and related documents are 

submitted electronically? What is the 

breakdown of the cost (e.g., software, 

programming, hardware, training)? 

• Would these costs differ depending 

on the type of entity providing services 

related to the application (e.g., sponsor, 

clinical research organization, U.S. 

agent)? 

• What additional costs are associated 

with implementing a particular format 

or standard for an electronic premarket 

submission? 

• Once the appropriate systems and 

processes are in place, and excluding 

startup costs, what would be the costs 

associated with providing an all-paper 

submission compared to an allelectronic submission? 

• Are there parts of a product 

application that are more costly to 

convert to an electronic format than 

others? 

3. Time 

• Based on your current method of 

preparation to submit applications, how 

much time would be required for 

preparation to submit the entire 

application in an electronic format; or a 

portion by an entity providing services 

related to the application? 

• How long would it take you to 

prepare and submit an application 

electronically under the current format 

accepted by FDA for voluntary 

submissions? 

• How much time would you need to 

make a smooth transition to a new 

electronic system? 

• How would your estimated time 

differ for various product types or 

applications? 

4. Implementation 

• Should we consider an incremental 

phase-in implementation strategy for an 

all-electronic submission environment? 

Is so, what should the strategy include? 

What is the order of priorities for 

phasing in implementation? 

• What steps can we take to minimize 

the cost or other burdens of 

transitioning to an all-electronic 

submission environment? 

• What additional standards or 

revisions to current electronic standards 

would be helpful to make electronic 

submissions work? 

• Are the tools and formats currently 

available for FDA electronic 

submissions adequate? If not, why? 

What is needed? 

• Are there other submission 

mechanisms more suitable and 

beneficial than what is currently 

available (e.g., the electronic submission 

gateway)? 

• Are there factors, such as data 

formats or tools, for harmonization with 

other government entities, the private 

sector, or foreign regulatory authorities 

that could reduce costs or increase the 

benefits of electronic submissions? 

• Would issuing guidance be useful 

in helping with the transition? If so, 

what topics would you like addressed? 

B. Third Party Entities 

As previously described in section II 

of this document, we are considering 

issues related to the concept and 

feasibility of an electronic platform that 

would facilitate the exchange of clinical 

research information and other 

regulatory product information, and the 

role of a public private partnership in 

the creation and assessment of such a 

platform. In addition, we are 

considering whether the functions of the 

platform could be assumed by a private 

entity or entities with the relevant 

technological expertise. Therefore, we 

are interested in hearing your 

presentation on the following questions. 

• What are your general viewpoints 

on a third party entity or entities 

providing services related to such an 

electronic platform? 

• What are your views on the 

establishment of a public-private 

partnership to initiate formation of an 

electronic platform? 

• How do you envision the business 

process modeling and nature of the 

third party entity or entities? 

• What are the necessary attributes 

and characteristics of the third party 

entity or entities? 

• What services could the third party 

entity or entities provide? 

• What collaborative efforts by FDA 

with a third party entity would be 

beneficial to establish services? 

V. Notice of Hearing Under 21 CFR Part 

15 

The Acting Commissioner of Food 

and Drugs (the Acting Commissioner) is 

announcing that the public hearing will 

be held in accordance with part 15 (21 

CFR part 15). The hearing will be 

conducted by a presiding officer, who 

will be accompanied by FDA senior 

management from the Office of the 

Commissioner, the Office of Policy and 

Planning, the Office of the Chief 

Counsel; and by senior management 

from the National Institutes of Health, 

particularly the National Cancer 

Institute. 

Persons who wish to participate in the 

part 15 hearing must file a written or 

electronic notice of participation with 

the Division of Dockets Management 

(see ADDRESSES and DATES). To ensure 

timely handling, any outer envelope 

should be clearly marked with the 

docket number found in brackets in the 

heading of this document, along with 

the statement ‘‘Electronic Submission of 

Regulatory Information, and Creating an 

Electronic Platform for Enhanced 

Information Management.’’ Requests to 

make a presentation should contain the 

potential presenter’s name and title; 

address; telephone and fax number; email address; affiliation, if any; the 

sponsor of the presentation (e.g., the 

organization paying travel expenses or 

fees), if any; and a brief summary of the 

presentation (including the discussion 

topic(s) that will be addressed). 

Under § 15.30(f), the hearing is 

informal, and the rules of evidence do 

not apply. No participant may interrupt 

the presentation of another participant. 

Only the presiding officer and panel 

members may question any person 

during or at the conclusion of each 

presentation. 

Public hearings under part 15 are 

subject to FDA’s policy and procedures 

for electronic media coverage of FDA’s 

public administrative proceedings (part 

10, subpart C (21 CFR part 10, subpart 

C)). Under § 10.205, representatives of 

the electronic media may be permitted, 

subject to certain limitations, to 

videotape, film, or otherwise record 

FDA’s public administrative 

proceedings, including presentations by 

participants. 

To the extent that the conditions for 

the hearing, as described in this 


sroberts on PROD1PC70 with NOTICES
Federal Register / Vol. 71, No. 224 / Tuesday, November 21, 2006 / Notices 67359 

document, conflict with any provisions 

set out in part 15, this document acts as 

a waiver of those provisions as specified 

in § 15.30(h). 

VI. Request for Comments 

Interested persons may submit to the 

Division of Dockets Management (see 

ADDRESSES) written or electronic notices 

of participation and comments for 

consideration. To permit time for all 

interested persons to submit data, 

information, or views on this subject, 

the administrative record of the hearing 

will remain open until February 16, 

2007. Persons who wish to provide 

additional materials for consideration 

should file these materials with the 

Division of Dockets Management (see 

ADDRESSES). You should annotate and 

organize your comments to identify the 

specific questions identified by topic to 

which they refer (see section IV of this 

document). Two paper copies of any 

mailed comments are to be submitted, 

except that individuals may submit one 

paper copy. Comments are to be 

identified with the docket number at the 

heading of this document. Received 

comments may be seen in Division of 

Dockets Management (see ADDRESSES) 

between 9 a.m. and 4 p.m., Monday 

through Friday. 

VII. Transcripts 

The hearing will be transcribed as 

stipulated in § 15.30(b). Transcripts of 

the hearing will be available for review 

at the Division of Dockets Management 

(see ADDRESSES) and on the Internet at 

http://www.fda.gov/ohrms/dockets 

approximately 21 days after the hearing. 

You may place orders for copies of the 

transcript through the Freedom of 

Information Office (HFI–35), Food and 

Drug Administration, 5600 Fishers lane, 

rm. 6–30, Rockville, MD 20857, at a cost 

of 10 cents per page. 

Dated: November 15, 2006. 

Janet Woodcock, 

Deputy Commissioner for Operations. 

[FR Doc. 06–9313 Filed 11–16–06; 2:12 pm] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Research 

Resources; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Center for 

Research Resources Special Emphasis Panel; 

RCMI Teleconference (II). 

Date: December 6, 2006. 

Time: 2 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, One 

Democracy Plaza, 6701 Democracy 

Boulevard, Bethesda, MD 20892 (Telephone 

Conference Call). 

Contact Person: Guo Zhang, PhD, MPH, 

Scientific Review Administrator, Office of 

Review, National Center for Research 

Resources, National Institutes of Health, 6701 

Democracy Boulevard, 1 Democracy Plaza, 

Room 1064, Bethesda, MD 20892, (301) 435–

0812, zhanggu@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research; 93.371, Biomedical 

Technology; 93.389, Research Infrastructure, 

93.306, 93.333, National Institutes of Health, 

HHS) 

Dated: November 14, 2006. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 06–9320 Filed 11–20–06; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Eye Institute; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Eye Institute 

Special Emphasis Panel; NEI K’s, R24’s and 

R34’s. 

Date: December 8, 2006. 

Time: 8:30 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Embassy Suites at the Chevy Chase 

Pavilion, 4300 Military Road, NW., 

Washington, DC 20015. 

Contact Person: Samuel Rawlings, PhD, 

Chief, Scientific Review Branch, Division of 

Extramural Research, National Eye Institute, 

5635 Fishers Lane, Suite 1300, MSC 9300, 

Bethesda, MD 20892–9300, 301–451–2020, 

rawlings@nei.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.867, Vision Research, 

National Institutes of Health, HHS) 

Dated: November 15, 2006. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 06–9300 Filed 11–21–06; 8:45am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Eye Institute; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the 

Board of Scientific Counselors, National 

Eye Institute. 

The meeting will be closed to the 

public as indicated below in accordance 

with the provisions set forth in section 

552b(c)(6), Title 5 U.S.C., as amended 

for the review, discussion, and 

evaluation of individual grant 

applications conducted by the National 

Eye Institute, including consideration of 

personnel qualifications and 

performance, and the competence of 

individual investigators, the disclosure 

of which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: Board of Scientific 

Counselors, National Eye Institute. 

Date: December 3–5, 2006. 

Time: 7 a.m. to 1 p.m. 

Agenda: To review and evaluate personal 

qualifications and performance, and 

competence of individual investigators. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, Room 6, 

Bethesda, MD 20892. 

Contact Person: Sheldon S Miller, PhD, 

Scientific Director, National Institutes of 

Health, National Eye Institute, Bethesda, MD 

20892, (301) 451–6763. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NIH campus. All visitor vehicles, 


sroberts on PROD1PC70 with NOTICES